SkinCure Oncology Achieves Major Milestone with 150,000th GentleCure Patient

SkinCure Oncology Hits 150,000 Patient Milestone with GentleCure® Treatment

In recent news, SkinCure Oncology has reached an impressive milestone by treating over 150,000 patients with its groundbreaking GentleCure® treatment for nonmelanoma skin cancer (NMSC). This remarkable achievement underscores the growing acceptance and demand for nonsurgical cancer treatments among patients across the United States.

The GentleCure Experience℠, which utilizes Image-Guided Superficial Radiation Therapy (IGSRT), provides an effective alternative for individuals diagnosed with skin cancers such as basal cell carcinoma and squamous cell carcinoma. Traditional treatment options often involve invasive approaches, including Mohs surgery, which can lead to complications such as pain and scarring. SkinCure's innovative methodology was designed to eliminate these drawbacks.

The 150,000th patient, Lacye Martini, a 55-year-old business owner from Louisiana, shared her journey of being diagnosed with basal cell carcinoma. After learning about her condition, she was mostly informed that surgery was the only available option. Concerned about having a surgical procedure close to her eye, she sought a second opinion. Thankfully, a friend recommended investigating Image-Guided SRT, which ultimately led her to Dr. Janine Hopkins, a board-certified dermatologist in Monroe, Louisiana, who was familiar with the GentleCure protocol.

Lacye expressed her surprise at how many healthcare providers may not adequately inform their patients about nonsurgical treatment options. She noted that her initial dermatologist’s office failed to refer her for GentleCure, believing that patients might reject this treatment due to the series of sessions required. This lack of communication highlights an essential aspect of patient care; every patient should be aware of all available options in order to make fully informed decisions about their health.

Dr. Hopkins met with Lacye and detailed the GentleCure treatment process, including its benefits and risks. The treatment protocol involves approximately 20 short sessions, lasting about 15 minutes each, boasting a success rate comparable to that of surgically invasive methods. The comfort Lacye experienced throughout her treatment journey, combined with no pain or significant side effects, reinforced her belief in the efficacy of GentleCure.

During her daily commutes to Dr. Hopkins' practice, Lacye took the opportunity to listen to podcasts, gaining confidence while undergoing her treatment. After completing the series of sessions, Dr. Hopkins conducted an ultrasound to confirm that the cancer had been effectively treated, resulting in a satisfactory cosmetic outcome. The only visible mark on Lacye's face is a minor scar resulting from the original biopsy, a stark contrast to what could have been had she chosen the surgical route.

Lacye expressed gratitude for discovering the GentleCure option before undergoing invasive surgery. She hopes that sharing her experience inspires others facing similar circumstances to research and advocate for themselves regarding their treatment options. Meanwhile, SkinCure Oncology’s CEO, Kerwin Brandt, praised the enthusiasm for GentleCure, emphasizing that healthcare providers should consider this method for eligible patients with early-stage NMSC.

SkinCure Oncology will continue to champion the GentleCure Experience℠ as a critical evolution in skin cancer treatment. Their dedication to providing high-quality, patient-centered approaches through partnerships with dermatology practices throughout the country reflects a commitment to enhancing patient outcomes. With over 500 physicians now offering GentleCure, the future looks bright for nonsurgical approaches to skin cancer care.

To learn more about SkinCure Oncology and the GentleCure treatment, you can explore their website at SkinCureOncology.com or visit GentleCure.com for invaluable informational resources targeted towards patients.